Compare SPDR Gold Trust (GLD) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Johnson & Johnson — how do they compare? SPDR Gold Trust trades at $384.42 (market cap $139.66B), while Johnson & Johnson trades at $260.42 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 4.4× SPDR Gold Trust's market cap, and Johnson & Johnson pays a 2.09% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Johnson & Johnson for 129 Days on average.
| GLD | JNJ | |
|---|---|---|
Market Cap | $139.66B | $618.09B |
Volume | 9,544,773 | 6,050,983 |
52-Week High | $495.90 | $278.43 |
52-Week Low | $362.32 | $186.00 |
Typical Hold Time | 74 Days | 129 Days |
Sector | — | Health |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, trades at $384.77 with a 2.37% daily gain amid bearish technical signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate expectations, though recent weak employment data provided temporary support. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. The ETF is testing key resistance levels with support at $373-$377 and resistance at $380-$384.
The outlook remains cautious as gold faces headwinds from monetary policy tightening and dollar strength. While serving as a traditional inflation hedge, GLD's near-term performance depends on interest rate trajectory and safe-haven demand. Risks include further Fed hawkishness and declining institutional interest, though long-term diversification benefits persist for portfolio allocation.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
